These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 26091736)

  • 21. [Economic evaluation of combined therapy in chronic hepatitis C].
    Casado MA; Buti M; Fosbrook L; Esteban R
    Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():57-62. PubMed ID: 11968346
    [No Abstract]   [Full Text] [Related]  

  • 22. Hepatitis C Treatment in Prisons - Incarcerated People's Uncertain Right to Direct-Acting Antiviral Therapy.
    Daniels AM; Studdert DM
    N Engl J Med; 2020 Aug; 383(7):611-613. PubMed ID: 32786186
    [No Abstract]   [Full Text] [Related]  

  • 23. [Cost-efficacy of new antiviral treatments for chronic hepatitis C].
    Lens S; Bonacci M
    Aten Primaria; 2015 Oct; 47(8):479-81. PubMed ID: 26433699
    [No Abstract]   [Full Text] [Related]  

  • 24. Cost-effectiveness of interferon treatment for hepatitis C.
    van Leeuwen DJ
    JAMA; 1999 Jun; 281(22):2083-4. PubMed ID: 10367810
    [No Abstract]   [Full Text] [Related]  

  • 25. The cost-effectiveness of novel direct acting antiviral agent therapies for the treatment of chronic hepatitis C.
    Bickerstaff C
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):787-800. PubMed ID: 26289734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of treatment for chronic hepatitis C infection.
    Dore GJ; Thein HH
    JAMA; 2003 Oct; 290(15):1993; author reply 1994. PubMed ID: 14559947
    [No Abstract]   [Full Text] [Related]  

  • 27. Cost-effectiveness of treatment for chronic hepatitis C infection.
    Bernstein D
    JAMA; 2003 Oct; 290(15):1993; author reply 1994. PubMed ID: 14559948
    [No Abstract]   [Full Text] [Related]  

  • 28. Accessing the cure: helping patients with hepatitis C overcome barriers to care.
    Rodriguez C; Reynolds A
    Am J Manag Care; 2016 Mar; 22(4 Suppl):s108-12. PubMed ID: 27270155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of interferon alfa 2b and ribavirin in the treatment of chronic hepatitis C.
    Kim WR; Poterucha JJ; Gross JB
    Hepatology; 2000 Mar; 31(3):807-8. PubMed ID: 10722315
    [No Abstract]   [Full Text] [Related]  

  • 30. Cost-effectiveness of interferon treatment for hepatitis C.
    Henley E
    JAMA; 1999 Jun; 281(22):2083; author reply 2084. PubMed ID: 10367809
    [No Abstract]   [Full Text] [Related]  

  • 31. Q & A with Karen Tashima, MD new direct-acting antiviral agents offer therapeutic revolution for hepatitis C virus infection.
    Korr M
    R I Med J (2013); 2014 Jul; 97(7):29-30. PubMed ID: 24983018
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment for hepatitis C virus infection in India: Promising times.
    Abraham P
    Indian J Med Microbiol; 2016; 34(3):273-4. PubMed ID: 27514946
    [No Abstract]   [Full Text] [Related]  

  • 33. Understanding Cost and Value in Hepatitis C Therapy.
    Linas BP
    Top Antivir Med; 2016; 24(2):93-97. PubMed ID: 27841979
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Direct costs of first-generation protease inhibitors for the treatment of genotype 1 chronic hepatitis C viral infection.
    Sethi N; Tapper EB; Vong A; Sethi S; Rourke M; Afdhal NH
    J Viral Hepat; 2015 Dec; 22(12):974-6. PubMed ID: 26010946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Cost-effectiveness of chronic hepatitis C treatment in Spain].
    Haj-Ali Saflo O; Hernández Guijo JM
    Gastroenterol Hepatol; 2009; 32(7):472-82. PubMed ID: 19615787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Hepatitis C in Egypt, a iatrogenic epidemic].
    Vrolijk JM; Schalm SW
    Ned Tijdschr Geneeskd; 2000 Dec; 144(49):2378. PubMed ID: 11129975
    [No Abstract]   [Full Text] [Related]  

  • 37. Effective but expensive hepatitis C treatment for patients with HIV.
    Harper KN
    AIDS; 2015 Oct; 29(16):N17. PubMed ID: 26544588
    [No Abstract]   [Full Text] [Related]  

  • 38. The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK.
    McEwan P; Bennett H; Ward T; Webster S; Gordon J; Kalsekar A; Yuan Y; Brenner M
    Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):173-80. PubMed ID: 26545086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treating hepatitis C in the prison population is cost-saving.
    Tan JA; Joseph TA; Saab S
    Hepatology; 2008 Nov; 48(5):1387-95. PubMed ID: 18924228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination therapy in naive patients with chronic hepatitis C: more value for the money.
    Koff RS
    J Hepatol; 2000 Oct; 33(4):664-6. PubMed ID: 11059875
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.